MNG1032
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.330
- MTORC1_SIGNALING+0.327
- PEROXISOME+0.314
- ANDROGEN_RESPONSE+0.280
- PROTEIN_SECRETION+0.246
- MYOGENESIS+0.218
- GLYCOLYSIS+0.217
- APICAL_SURFACE+0.214
- PANCREAS_BETA_CELLS+0.214
- UNFOLDED_PROTEIN_RESPONSE+0.204
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.392
- ALLOGRAFT_REJECTION-0.362
- TNFA_SIGNALING_VIA_NFKB-0.348
- INTERFERON_GAMMA_RESPONSE-0.341
- INFLAMMATORY_RESPONSE-0.327
- INTERFERON_ALPHA_RESPONSE-0.326
- WNT_BETA_CATENIN_SIGNALING-0.280
- IL2_STAT5_SIGNALING-0.236
- NOTCH_SIGNALING-0.191
- COMPLEMENT-0.161
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0095123 | — | — | 0.742 |
| 2 | R397 | — | — | 0.740 |
| 3 | SRR25617914 | — | C | 0.736 |
| 4 | SRR8518435 | — | F | 0.733 |
| 5 | TCGA-AN-A0FV-01A-11R-A00Z-07 | — | C | 0.725 |
| 6 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.723 |
| 7 | BSR_19_0079_A1_S53 | — | B | 0.714 |
| 8 | SRR8518424 | — | C | 0.709 |
| 9 | TCGA-BH-A0HY-01A-11R-A056-07 | — | C | 0.708 |
| 10 | 97591eeb-89dc-4b70-92d4-2bb70d263098 | — | — | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.327 | Inavolisib | — uncovered |
| PEROXISOME | 0.314 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.246 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.218 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.217 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.214 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.214 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.204 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.173 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.166 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.158 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.144 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.135 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.131 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.123 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.108 | Temsirolimus | — uncovered |